About BGNE

BeiGene is a global, clinical-stage, research-based biotechnology company focused on molecularly targeted and immuno-oncology cancer therapeutics. With a team of over 300 scientists, clinicians and staff in mainland China, the United States, Australia and Taiwan, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients.
Primary Exchange: NASDAQ
SIC Pharmaceutical Preparations
NAICS Pharmaceutical Preparation Manufacturing

BGNE is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
BIB ProShares Ultra Nasdaq Biotechnology 212.2 M 2.1215E+08 234 234 0.27% 0.00268345 1.2 M 1248680
UBIO Proshares UltraPro Nasdaq Biotechnology 28.4 M 2.839E+07 227 227 0.17% 0.00172144 160 K 159504
ADRA Invesco BLDRS Asia 50 ADR Index Fund 18.4 M 1.84E+07 50 50 0.29% 0.00291 54 K 53542
ADRE Invesco BLDRS Emerging Markets 50 ADR Index Fund 133.7 M 1.337E+08 50 50 0.39% 0.00388 517 K 517496
BBH VanEck Vectors Biotech ETF 371.3 M 3.713E+08 25 25 3.71% 0.0371 13.8 M 1.38488E+07
IBB iShares Nasdaq Biotechnology Index Fund 7.3 B 7.33983E+09 221 221 0.64% 0.0064 47.4 M 4.73718E+07
ONEQ Fidelity Nasdaq Composite Index Tracking Stock 2.1 B 2.1E+09 1,002 1002 0.03% 0.000308062 648 K 647518